Scott R. Armstrong - Concepedia

Author

Scott R. Armstrong

Also Known As

Armstrong, Scott R., S R Armstrong, S. R. ARMSTRONG, S. R. Armstrong, Sally Armstrong, Scott Armstrong, Scott R Armstrong, Scott R. Armstrong

Publications

428

Citations

H-Index

Concepts

All Affiliations

Theravance Biopharma (United States)

About

Scott R. Armstrong is an author at Theravance Biopharma (United States) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	204
2	Gastroenterology	3	3	54
3	Health Sciences	2	2	30
4	Immunology	1	1	18
5	Pathology	1	1	14

Scott R. Armstrong

Publications

386

Citations

H-Index

Page 1

	Year	Citations
The 5‐HT<sub>4</sub> receptor agonist, tegaserod, is a potent 5‐HT<sub>2B</sub> receptor antagonist <i>in vitro</i> and <i>in vivo</i> David T. Beattie, Jacqueline A.M. Smith, Daniel G. Marquess, British Journal of Pharmacology	2004	119
Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat Laxminarayan G. Hegde, Cecile Yu, Travis Renner, Journal of Cardiovascular Pharmacology HypertensionCardiovascular PharmacologyPharmacotherapyBlood PressureAtherosclerosis	2011	64
The in vivo gastrointestinal activity of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity David T. Beattie, Scott R. Armstrong, J P Shaw, Naunyn-Schmiedeberg s Archives of Pharmacology Signal TransductionFunctional SelectivityGastrointestinal PharmacologyMedicinePhysiology	2008	46
The Pharmacology of TD-8954, a Potent and Selective 5-HT4 Receptor Agonist with Gastrointestinal Prokinetic Properties David T. Beattie, Scott R. Armstrong, Ross G. Vickery, Frontiers in Pharmacology	2011	42
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT4 receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation Daniel D. Long, Scott R. Armstrong, David T. Beattie, Bioorganic & Medicinal Chemistry Letters Functional Gastrointestinal DisorderGastrointestinal PharmacologyMedicineGastroenterologyVivo Efficacy	2012	22
A Multivalent Approach to the Design and Discovery of Orally Efficacious 5-HT<sub>4</sub>Receptor Agonists R. Murray McKinnell, Scott R. Armstrong, David T. Beattie, Journal of Medicinal Chemistry	2009	21
Discovery of TD-8954, a clinical stage 5-HT4 receptor agonist with gastrointestinal prokinetic properties R. Murray McKinnell, Scott R. Armstrong, David T. Beattie, Bioorganic & Medicinal Chemistry Letters Gastrointestinal Prokinetic PropertiesSignal TransductionFunctional SelectivityMedicineImmunology	2013	18
The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity Scott R. Armstrong, Christina Campbell, Carrie Richardson, Naunyn-Schmiedeberg s Archives of Pharmacology Gastrointestinal PharmacologyMedicinePhysiologyVivo PharmacodynamicsPharmacological Agent	2013	18
Measurement of 5-HT4 receptor-mediated esophageal responses by digital sonomicrometry in the anesthetized rat Scott R. Armstrong, Julia L. McCullough, David T. Beattie Journal of Pharmacological and Toxicological Methods Digital SonomicrometryEsophagusPhysiologyGastroenterologyPathology	2005	14
The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist Pamela R. Tsuruda, Ross G. Vickery, Daniel D. Long, Naunyn-Schmiedeberg s Archives of Pharmacology Molecular PharmacologyMedicineDrug DiscoveryPharmacological AgentNeuropharmacology	2013	12

Page 1